West Announces Third-Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
West Pharma (WST) Tops Q3 EPS by 8c, Revenues Beat; Raises FY19 EPS/Revenue Guidance Above Consensus
October 24, 2019 6:15 AM EDTWest Pharma (NYSE: WST) reported Q3 EPS of $0.79, $0.08 better than the analyst estimate of $0.71. Revenue for the quarter came in at $456.1 million versus the consensus estimate of $450.94 million.
Third-Quarter 2019 Summary (comparisons to prior-year period)
Net sales of $456.1 million grew 5.7%; organic sales growth was 7.9%; sales from a recent acquisition contributed an additional 20 basis points of growth; currency translation reduced sales by 240 basis points.Reported-diluted EPS of $0.75 increased 3%.Adjusted-diluted EPS of $0.79 increased 4%.Company is raising its full-year 2019 net sales guidance to a new range of between $1.815 billion and $1.825... More